<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-18672" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Brugada Syndrome</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>El Sayed</surname>
            <given-names>Moustafa</given-names>
          </name>
          <aff>Louisiana State Un HSC Shreveport</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Goyal</surname>
            <given-names>Amandeep</given-names>
          </name>
          <aff>University of Kansas Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Callahan</surname>
            <given-names>Avery L.</given-names>
          </name>
          <aff>Louisiana State University HSC</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Moustafa El Sayed declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Amandeep Goyal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Avery Callahan declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-18672.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Brugada syndrome is a rare but potentially life-threatening inherited disease that predisposes patients to fatal cardiac arrhythmias. The syndrome is characterized by the ECG findings of a right bundle branch block and ST-segment elevations in the right precordial leads (V1-V3). This activity outlines the evaluation and management of Brugada syndrome and explains the roles of the interprofessional team in caring for patients with patients with Brugada syndrome.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the etiology and epidemiology of Brugada syndrome.</p></list-item><list-item><p>Summarize the pathophysiology of Brugada syndrome.</p></list-item><list-item><p>Outline the typical presentation and evaluation of a patient with Brugada syndrome.</p></list-item><list-item><p>Explain the importance of improving care coordination among the interprofessional team to improve outcomes for patients affected by Brugada syndrome.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18672&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18672">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-18672.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Brugada syndrome is a genetic disease that predisposes patients to fatal cardiac arrhythmias.&#x000a0;It&#x000a0;is named after Josep and Pedro Brugada who first described it in 1992. The syndrome is characterized by&#x000a0;the ECG findings of a right bundle branch block and ST-segment elevations in the&#x000a0;right precordial leads (V1-V3).&#x000a0;<xref ref-type="bibr" rid="article-18672.r1">[1]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-18672.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The first genetic association with Brugada syndrome discovered was a loss-of-function mutation&#x000a0;in&#x000a0;the cardiac voltage-gated sodium channel gene SCN5A. It&#x000a0;is thought to be found&#x000a0;in 15-30% of Brugada Syndrome cases. <xref ref-type="bibr" rid="article-18672.r2">[2]</xref>&#x000a0;Mutations in calcium and potassium channels, associated channel proteins, and&#x000a0;desmosomal proteins have also been&#x000a0;linked with the disease. Brugada syndrome is inherited in an autosomal dominant pattern; however, affected individuals may&#x000a0;demonstrate&#x000a0;variable expressivity&#x000a0;and reduced penetrance. Additionally,&#x000a0;many environmental and genetic factors may influence the phenotype, including temperature, medications, electrolyte abnormalities, and cocaine.<xref ref-type="bibr" rid="article-18672.r3">[3]</xref></p>
      </sec>
      <sec id="article-18672.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The prevalence of Brugada Syndrome&#x000a0;is approximately 3 to 5 per 10,000 people.&#x000a0;Brugada syndrome is approximately 8 to 10 times more common in males than females. This gender difference, however, is not found in pediatric patients.&#x000a0;This has been hypothesized to be due to&#x000a0;higher testosterone levels after puberty and different proportions of ionic&#x000a0;currents based on sex.&#x000a0;Brugada syndrome is also more prevalent&#x000a0;in&#x000a0;those who are&#x000a0;of Southeast Asian descent. The mean affected age is 41 years old. Brugada syndrome accounts for 4%&#x000a0;of all sudden cardiac deaths.&#x000a0;<xref ref-type="bibr" rid="article-18672.r3">[3]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-18672.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The exact mechanism for Brugada Syndrome is not clear. There are&#x000a0;two main physiologic hypotheses that have been suggested: the repolarization&#x000a0;disorder and the depolarization disorder models. According to the repolarization disorder model, the decrease in sodium current secondary to the loss-of-function sodium channel mutation&#x000a0;causes the right ventricular epicardium's action potential to have a deeper notch when compared to the action potential of the endocardium. This difference in current can lead to the&#x000a0;typical EKG finding of Brugada syndrome and&#x000a0;subsequent fatal arrhythmias. The depolarization disorder model, on the other hand, suggests that the EKG findings of Brugada syndrome are&#x000a0;secondary to a delay in depolarization due to slow conduction in the right ventricular outflow tract.</p>
      </sec>
      <sec id="article-18672.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>When Brugada syndrome was first described, it was thought to be only in structurally normal hearts. However,&#x000a0;newer research revealed right ventricular outflow tract abnormalities, such as an increase in adipose tissue and fibrosis. These structural abnormalities support&#x000a0;the depolarization disorder model as a possible&#x000a0;cause of slower conduction in the right ventricular outflow tract. Nonetheless, whether these structural abnormalities account for the arrhythmias&#x000a0;caused in Brugada syndrome or that they are the result of the disease and aging process is still a matter of debate.&#x000a0;<xref ref-type="bibr" rid="article-18672.r4">[4]</xref></p>
      </sec>
      <sec id="article-18672.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Symptoms of Brugada syndrome range from&#x000a0;the absence&#x000a0;of any symptoms to sudden cardiac death. Sudden cardiac death typically occurs during sleep, possibly secondary to increased vagal tone. Approximately 80% of Brugada syndrome patients who develop ventricular tachycardia or ventricular fibrillation experience syncope. Palpitations and dizziness have also been described as possible&#x000a0;symptoms. History of a febrile illness may be present&#x000a0;as fever may precipitate symptoms and arrhythmias. 10 to 30% of&#x000a0;Brugada syndrome patients will have an atrial&#x000a0;arrhythmia,&#x000a0;and supraventricular tachycardia is also more&#x000a0;common in Brugada syndrome patients than the general population. However, 72% of those with Brugada syndrome will not show any symptoms, and 28% will not have a family history of sudden cardiac death.</p>
      </sec>
      <sec id="article-18672.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>A 12-lead electrocardiogram is significant&#x000a0;to both diagnose and decide management options of Brugada syndrome. Three different ECG patterns have been described in Brugada syndrome patients: coved ST elevations greater than 2 mm accompanied with an inverted T wave (type I), saddleback-shaped ST elevation greater than 2 mm (type II), and saddle-back shaped ST elevations less than 2 mm (type III). Additionally, patients with a normal ECG and high-risk factors may require a drug challenge test to reveal the typical ECG findings of ST elevations in the precordial leads V1 to V3. These high-risk factors that may require provocative drug testings include having a family history of Brugada syndrome, family history of sudden cardiac death,&#x000a0;and symptoms&#x000a0;consistent with Brugada syndrome in the setting of questionable ECG abnormalities.&#x000a0;<xref ref-type="bibr" rid="article-18672.r3">[3]</xref></p>
        <p>Class IA antiarrhythmics (such as procainamide and ajmaline) and IC antiarrhythmics (such as flecainide and propafenone), which act as sodium channel blockers, are the drugs used in the challenge test. Brugada ECG findings may also be revealed after cocaine use or tricyclic antidepressant toxicity. Electrolyte abnormalities, such as hyperkalemia and hypercalcemia have been known to&#x000a0;reveal ST elevations in the right precordial leads.<xref ref-type="bibr" rid="article-18672.r5">[5]</xref></p>
        <p>If a drug challenge test is normal in a pediatric patient, it may require repetition after the child reaches puberty, given the hormonal effects on Brugada syndrome phenotype. Another diagnostic test described to&#x000a0;expose the ST elevations of Brugada syndrome is the full stomach test, where ECGs are obtained before and after a large meal, which&#x000a0;causes an increase in vagal tone.&#x000a0;Other&#x000a0;tests that may be useful for some patients&#x000a0;include genetic testing for SCN5A mutations and invasive electrophysiology.&#x000a0;<xref ref-type="bibr" rid="article-18672.r3">[3]</xref></p>
      </sec>
      <sec id="article-18672.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>An implantable cardioverter-defibrillator (ICD) is the mainstay of treatment of Brugada syndrome patients. Current recommendations are to perform ICD placement in those who survived cardiac arrest, patients with Brugada ECG abnormalities and syncope, and those who can have Brugada ECG findings on drug challenge tests. Pharmacological treatment with quinidine is also an option. There are conflicting results about using quinidine instead of ICD placement; however, quinidine is useful in Brugada syndrome patients with an ICD who experience multiple shocks and in those who have&#x000a0;contraindications for ICD placement. Finally, radio frequency ablation of the anterior part of the right ventricular outflow tract is a new, emerging therapy with a promising prognosis for&#x000a0;Brugada syndrome patients. Treatment of asymptomatic&#x000a0;individuals with Brugada syndrome ECG findings is more complicated. Personalized risk-stratification is essential in providing the right management for&#x000a0;these asymptomatic patients depending on their risk factors using a multi-disciplinary approach and with close and frequent follow-up.&#x000a0;<xref ref-type="bibr" rid="article-18672.r6">[6]</xref></p>
      </sec>
      <sec id="article-18672.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Many of the conditions that may be mistaken for Brugada syndrome also cause syncope as a common symptom. Standard of care for evaluation of syncope is to obtain a 12-lead ECG to evaluate for many of&#x000a0;such diseases that may resemble Brugada syndrome. These diseases include QT prolongation, Wolff-Parkinson-White syndrome, pulmonary embolism, sick sinus syndrome, early repolarization syndrome, electrolyte abnormalities, and atrial fibrillation.&#x000a0;<xref ref-type="bibr" rid="article-18672.r3">[3]</xref></p>
      </sec>
      <sec id="article-18672.s11" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Brugada syndrome is not very&#x000a0;common, but because it is associated with sudden death, it is important for healthcare workers to be aware of the ECG presentation. The disorder is best managed by an interprofessional team that includes a cardiologist, electrophysiologist&#x000a0;and a genetic counselor. The key to diagnosis is a comprehensive medical history of syncopal attacks, chest discomfort or dizziness. Once the diagnosis is made, patients need to be educated about the potential for cardiac arrest. While an ICD is routinely implanted in these patients, it also predisposes them to device-related complications and inappropriate shocks. The actual incidence of death from Brugada syndrome is not known but may account for 3-20% of all sudden deaths in patients with structurally normal hearts. Sudden deaths tend to&#x000a0;occur early after the fourth decade of life. The patient, family, and&#x000a0;coworkers must be educated about the basics of CPR. Once the diagnosis of Brugada syndrome is made, genetic counseling should be offered to the family.<xref ref-type="bibr" rid="article-18672.r7">[7]</xref><xref ref-type="bibr" rid="article-18672.r8">[8]</xref> (Level V)</p>
      </sec>
      <sec id="article-18672.s12">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18672&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18672">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/heart-health/brugada-syndrome/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=18672">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/18672/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=18672">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-18672.s13">
        <fig id="article-18672.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Brugada syndrome type 1. Note that V5 is placed one intercostal space above V1 (V1 IC4) and V6 is placed one intercostal space above V2 (V2 IC3). Type I morphology is seen in V1, V1 IC3 and V2 IC3. Furthermore, there is a horizontal QRS axis, broad P waves, wide S waves in the lateral and inferior leads and fractionation of the QRS complex in III and aVL. Contributed by P.G. Postema, M.D., AMC</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="1280px-Brugada_syndrome_type1_example1_xCardioNetworks_ECGpediax" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-18672.s14">
        <fig id="article-18672.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Brugada syndrome Image courtesy S Bhimji MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="brugada" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-18672.s15">
        <title>References</title>
        <ref id="article-18672.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brugada</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Brugada</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>1992</year>
            <month>Nov</month>
            <day>15</day>
            <volume>20</volume>
            <issue>6</issue>
            <fpage>1391</fpage>
            <page-range>1391-6</page-range>
            <pub-id pub-id-type="pmid">1309182</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18672.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kapplinger</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Tester</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Alders</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Benito</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Berthet</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brugada</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Brugada</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fressart</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Guerchicoff</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Harris-Kerr</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kamakura</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kyndt</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Koopmann</surname>
                <given-names>TT</given-names>
              </name>
              <name>
                <surname>Miyamoto</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Pfeiffer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pollevick</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Probst</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Zumhagen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vatta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Towbin</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Shimizu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Schulze-Bahr</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Antzelevitch</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Salisbury</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Guicheney</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wilde</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Brugada</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Schott</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Ackerman</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>An international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing.</article-title>
            <source>Heart Rhythm</source>
            <year>2010</year>
            <month>Jan</month>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>33</fpage>
            <page-range>33-46</page-range>
            <pub-id pub-id-type="pmid">20129283</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18672.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sarquella-Brugada</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Campuzano</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Arbelo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Brugada</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Brugada</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Brugada syndrome: clinical and genetic findings.</article-title>
            <source>Genet Med</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-12</page-range>
            <pub-id pub-id-type="pmid">25905440</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18672.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meregalli</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Wilde</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>HL</given-names>
              </name>
            </person-group>
            <article-title>Pathophysiological mechanisms of Brugada syndrome: depolarization disorder, repolarization disorder, or more?</article-title>
            <source>Cardiovasc Res</source>
            <year>2005</year>
            <month>Aug</month>
            <day>15</day>
            <volume>67</volume>
            <issue>3</issue>
            <fpage>367</fpage>
            <page-range>367-78</page-range>
            <pub-id pub-id-type="pmid">15913579</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18672.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Littmann</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Monroe</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Kerns</surname>
                <given-names>WP</given-names>
              </name>
              <name>
                <surname>Svenson</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Gallagher</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Brugada syndrome and "Brugada sign": clinical spectrum with a guide for the clinician.</article-title>
            <source>Am Heart J</source>
            <year>2003</year>
            <month>May</month>
            <volume>145</volume>
            <issue>5</issue>
            <fpage>768</fpage>
            <page-range>768-78</page-range>
            <pub-id pub-id-type="pmid">12766732</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18672.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sieira</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dendramis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Brugada</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Pathogenesis and management of Brugada syndrome.</article-title>
            <source>Nat Rev Cardiol</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>13</volume>
            <issue>12</issue>
            <fpage>744</fpage>
            <page-range>744-756</page-range>
            <pub-id pub-id-type="pmid">27629507</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18672.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Louis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Calamaro</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Vinocur</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Hereditary arrhythmias and cardiomyopathies: decision-making about genetic testing.</article-title>
            <source>Curr Opin Cardiol</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>33</volume>
            <issue>1</issue>
            <fpage>78</fpage>
            <page-range>78-86</page-range>
            <pub-id pub-id-type="pmid">29059074</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18672.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mizusawa</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Recent advances in genetic testing and counseling for inherited arrhythmias.</article-title>
            <source>J Arrhythm</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>32</volume>
            <issue>5</issue>
            <fpage>389</fpage>
            <page-range>389-397</page-range>
            <pub-id pub-id-type="pmid">27761163</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
